Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells

Cyclin-dependent kinase inhibitors (CDKIs) are considered as novel anticancer agents because of their ability to induce growth arrest or apoptosis in tumour cells. It has not yet been fully determined, however, which CDKI is the best candidate for the treatment of malignant gliomas and whether norma...

Descripción completa

Detalles Bibliográficos
Autores principales: Komata, T, Kanzawa, T, Takeuchi, H, Germano, I M, Schreiber, M, Kondo, Y, Kondo, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747579/
https://www.ncbi.nlm.nih.gov/pubmed/12698196
http://dx.doi.org/10.1038/sj.bjc.6600862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747579/
https://www.ncbi.nlm.nih.gov/pubmed/12698196
http://dx.doi.org/10.1038/sj.bjc.6600862

Ejemplares similares